3 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Untitled document
    3
    1. karim2001khoury 19 Feb 2026
      Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

      [Paper-level Aggregated] PMCID: PMC7499606

      Evidence Type(s): Oncogenic, Prognostic

      Justification: Oncogenic: The TP53 Y220C missense mutation is described as a "deleterious somatic mutation," indicating its role in promoting cancer development. Prognostic: The patient's response to various treatments, including the combination therapy, suggests that the presence of the Y220C mutation may influence treatment outcomes and disease progression.

      Gene→Variant (gene-first): TP53(7157):Y220C

      Genes: TP53(7157)

      Variants: Y220C

      CIViC paper-level aggregated PMC7499606
    2. karim2001khoury 19 Feb 2026
      In the M6620-carboplatin combination cohort, a confirmed RECISTv1.1 PR was observed in a 54-year-old woman with heavily pretreated metastatic high-grade serous ovarian cancer, who was treated at the combination RP2D. Bio

      [Paragraph-level] PMCID: PMC7499606 Section: RESULTS PassageIndex: 18

      Evidence Type(s): Oncogenic, Predictive

      Justification: Oncogenic: The TP53 Y220C missense mutation is described as a "deleterious somatic mutation," indicating its contribution to tumor development or progression. Predictive: The passage discusses the patient's response to various therapies, including PARP inhibitors and the M6620-carboplatin combination therapy, suggesting that the Y220C variant may correlate with treatment response.

      Gene→Variant (gene-first): 7157:Y220C

      Genes: 7157

      Variants: Y220C

      CIViC paragraph-level PMC7499606 Oncogenic Predictive
    3. karim2001khoury 19 Feb 2026
      In the M6620-carboplatin combination cohort, a confirmed RECISTv1.1 PR was observed in a 54-year-old woman with heavily pretreated metastatic high-grade serous ovarian cancer, who was treated at the combination RP2D. Bio

      [Paragraph-level] PMCID: PMC7499606 Section: RESULTS PassageIndex: 18

      Evidence Type(s): Oncogenic, Predictive

      Justification: Oncogenic: The TP53 Y220C missense mutation is described as a "deleterious somatic mutation," indicating its contribution to tumor development or progression. Predictive: The passage discusses the patient's response to various therapies, including PARP inhibitors and the M6620-carboplatin combination therapy, suggesting that the Y220C variant may correlate with treatment response.

      Gene→Variant (gene-first): 7157:Y220C

      Genes: 7157

      Variants: Y220C

      CIViC paragraph-level PMC7499606 Oncogenic Predictive
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC7499606/pdf/JCO.19.02404.pdf